Searchable abstracts of presentations at key conferences in endocrinology

ea0090p331 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Exploration of Clinical Improvements Following Setmelanotide in Patients With Bardet-Biedl Syndrome

Haqq Andrea M. , Chung Wendy , Dollfus Helene , Iqbal Anoop , A. Martos-Moreno Gabriel , Poitou Christine , Yanovski Jack A. , Malhotra Sonali , Miller Paul , Yuan Guojun , Forsythe Elizabeth , Clement Karine , Argente Jesus

Background: In patients with Bardet-Biedl syndrome (BBS), signaling impairments in the melanocortin-4 receptor (MC4R) pathway lead to hyperphagia and severe obesity, which negatively impact quality of life (QOL). We evaluated the impact of setmelanotide, an MC4R agonist, on age-appropriate weight-related parameters, hunger, and QOL in a Phase 3 trial of patients with BBS to further characterize clinical benefit in this patient population.Methods: Patient...